Search results for "pyrrolidines"

showing 10 items of 66 documents

Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic

1999

Rationale: EMD 57445 (panamesine) is a high affinity sigma ligand with the profile of an atypical antipsychotic in animal studies. It has been reported recently to have antipsychotic activity in schizophrenia. However, its metabolite, EMD 59983, binds also to D2 and D3 dopamine (DA) receptors. Objectives: The aim of this study was to test, using single photon emission computed tomography (SPECT) and [123I]iodobenzamide (IBZM) as the radiotracer, whether EMD 59983 would pass the blood-brain barrier and to what extent it would contribute to the effects of EMD 57445 in schizophrenia. Methods: Two IBZM SPECT-scans were performed in five neuroleptic-free schizophrenic patients (DSM IV), one befo…

AdultMalemedicine.medical_specialtyPyrrolidinesmedicine.drug_classmedicine.medical_treatmentSigma receptorAtypical antipsychoticPanamesinePharmacologychemistry.chemical_compoundIodobenzamidePiperidinesDopamine receptor D3DopamineInternal medicinemedicineHumansReceptors sigmaAntipsychoticOxazolesTomography Emission-Computed Single-PhotonPharmacologyReceptors Dopamine D2Middle AgedCorpus StriatumPyrimidinesEndocrinologychemistryBlood-Brain BarrierDopamine receptorBenzamidesSchizophreniaFemaleAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study.

2011

Background Preclinical data implicate the reinforcing effects of alcohol to be mediated by interaction between the opioid and dopamine systems of the brain. Specifically, alcohol-induced release of β-endorphins stimulates μ-opioid receptors (MORs), which is believed to cause dopamine release in the brain reward system. Individual differences in opioid or dopamine neurotransmission have been suggested to be responsible for enhanced liability to abuse alcohol. In the present study, a single dose of the MOR agonist remifentanil was administered in detoxified alcohol-dependent patients and healthy control subjects to mimic the β-endorphin-releasing properties of ethanol and to assess the effect…

AgonistAdultMaleFluorine RadioisotopesPyrrolidinesmedicine.drug_classDopamineReceptors Opioid muPharmacologySeverity of Illness IndexRemifentanilRadioligand AssayDopamine receptor D1PiperidinesDopamine receptor D3DopaminemedicineLimbic SystemHumansBiological PsychiatryReceptors Dopamine D2PutamenFunctional NeuroimagingVentral striatumAlcohol dependenceMiddle AgedAnalgesics OpioidBehavior AddictiveAlcoholismmedicine.anatomical_structurenervous systemFallypridePositron-Emission TomographyBenzamidesPsychologymedicine.drugBiological psychiatry
researchProduct

Different muscarinic receptor subtypes modulate proliferation of primary human detrusor smooth muscle cells via Akt/PI3K and map kinases.

2013

While acetylcholine (ACh) and muscarinic receptors in the bladder are mainly known for their role in the regulation of smooth muscle contractility, in other tissues they are involved in tissue remodelling and promote cell growth and proliferation. In the present study we have used primary cultures of human detrusor smooth muscle cells (HDSMCs), in order to investigate the role of muscarinic receptors in HDSMC proliferation. Samples were obtained as discarded tissue from men >65 years undergoing radical cystectomy for bladder cancer and cut in pieces that were either immediately frozen or placed in culture medium for the cell culture establishment. HDSMCs were isolated from samples, propagat…

AtropineMalePyrrolidinesMessenger030232 urology & nephrologyGene ExpressionPhosphatidylinositol 3-Kinases0302 clinical medicineAged Atropine; pharmacology Benzofurans; pharmacology Carbachol; pharmacology Cell Proliferation Cells; Cultured Cholinergic Agonists; pharmacology Gene Expression Humans Male Mitogen-Activated Protein Kinases; metabolism Muscarinic Antagonists; pharmacology Myocytes; Smooth Muscle; metabolism Phosphatidylinositol 3-Kinases; metabolism Piperidines; pharmacology Pirenzepine; analogs /&/ derivatives/pharmacology Proto-Oncogene Proteins c-akt; metabolism Pyrrolidines; pharmacology RNA; Messenger; metabolism Receptors; Muscarinic; physiology Urinary Bladder; cytologyPiperidinesSmooth MuscleReceptorsMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptorCells CulturedCulturedMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2Smooth muscle contractionMuscarinic acetylcholine receptor M1Receptors Muscarinic030220 oncology & carcinogenesisMitogen-Activated Protein KinasesAcetylcholinemedicine.drugmedicine.medical_specialtyCarbacholCellsMyocytes Smooth MuscleUrinary BladderMuscarinic AntagonistsBiologyCholinergic Agonists03 medical and health sciencesInternal medicineMuscarinicmedicineHumansRNA MessengerAgedBenzofuransCell ProliferationPharmacologyMyocytesPirenzepineEndocrinologyphysiologycytologyRNACarbacholanalogs /&/ derivatives/pharmacologymetabolismProto-Oncogene Proteins c-aktPharmacological research
researchProduct

Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography.

2010

Abstract SSR149415 was the first non-peptide vasopressin-(V1b) receptor antagonist reported. It has been used to probe the role of V1b receptors in animal models of depression, aggression, and stress-anxiety, and was progressed to clinical trials for the treatment of depression. Due to the interest in V1b receptors as a therapeutic target and the growing use of SSR149415 in preclinical research, we developed a method to label SSR145419 with carbon-11 and have studied its pharmacokinetics in non-human primates using positron emission tomography.

BiodistributionReceptors VasopressinIndolesPyrrolidinesmedicine.drug_classClinical BiochemistryPharmaceutical ScienceAnxietyBiochemistryPreclinical researchAnimal models of depressionDrug DiscoverymedicineAnimalsCarbon RadioisotopesReceptorMolecular Biologymedicine.diagnostic_testbusiness.industryChemistryDepressionOrganic ChemistryAntagonistReceptor antagonistClinical trialBiochemistryAnti-Anxiety AgentsPositron emission tomographyPositron-Emission TomographyMolecular MedicineNuclear medicinebusinessAntidiuretic Hormone Receptor AntagonistsPapioBioorganicmedicinal chemistry letters
researchProduct

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

2012

This study compared the effect of Glimepiride versus Vildagliptin on β-cell function and the release of intact proinsulin (PI) in patients with type 2 diabetes mellitus. Patients on metformin monotherapy were randomized to add on treatment with Vildagliptin or Glimepiride. A standardized test meal was given at baseline, after 12 and 24 weeks of treatment. Insulin, PI and blood glucose values were measured in the fasting state and postprandial for 300 min. Fasting PI levels significantly decreased in the Vildagliptin group. The area under the curve for the postprandial release of PI decreased during Vildagliptin and increased during Glimepiride treatment. The proinsulin to insulin ratio decl…

Blood GlucoseMalemedicine.medical_specialtyPyrrolidinesendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdamantaneEndocrinologyDiabetes mellitusInternal medicineNitrilesInternal MedicinemedicineHumansHypoglycemic AgentsVildagliptinProinsulinVildagliptinDipeptidyl-Peptidase IV Inhibitorsbusiness.industryInsulinnutritional and metabolic diseasesType 2 Diabetes MellitusPostprandial Periodmedicine.diseaseMetforminMetforminGlimepirideSulfonylurea CompoundsTreatment OutcomePostprandialEndocrinologyDiabetes Mellitus Type 2Area Under CurveDrug Therapy CombinationFemalebusinessProinsulinmedicine.drugDiabetes, Obesity and Metabolism
researchProduct

Overexpression of Ogg1 in mammalian cells: effects on induced and spontaneous oxidative DNA damage and mutagenesis

1999

Chinese hamster ovary cell lines (AA8 and AS52) were stably transfected to overexpress hOgg1 protein, the human DNA repair glycosylase for 7,8-dihydro-8-oxoguanine (8-oxoG). In the transfectants, the repair rate of 8-oxoG residues induced by either potassium bromate or the photosensitizer [R]-1-[(10-chloro-4-oxo-3-phenyl-4H-benzo[a]quinolizin-1-yl)-carbo nyl ]-2-pyrrolidinemethanolplus light was up to 3-fold more rapid than in the parental cells. However, the improved repair had little effect on the mutagenicity of potassium bromate in the guanine phosphoribosyl transferase (gpt) locus of the OGG1-transfected AS52 cells. The steady-state (background) levels of DNA base modifications sensiti…

Cancer ResearchPyrrolidinesDNA RepairPhotochemistryDNA repairDNA damageBiologyTransfectionPolymerase Chain ReactionCell LineDNA-formamidopyrimidine glycosylasechemistry.chemical_compoundCricetulusGenes ReporterCricetinaeAnimalsheterocyclic compoundsN-Glycosyl HydrolasesPhotosensitizing AgentsBromatesChinese hamster ovary cellOvaryGeneral MedicineTransfectionDNA repair protein XRCC4OxidantsMolecular biologyOxidative StressDNA-Formamidopyrimidine GlycosylasechemistryGenes BacterialMutagenesisDNA glycosylaseEnzyme InductionFemaleQuinolizinesDNADNA DamageCarcinogenesis
researchProduct

Atropine-resistant effects of the muscarinic agonists McN-A-343 and AHR 602 on cardiac performance and the release of noradrenaline from sympathetic …

1974

Abstract 1 The effects of 4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium chloride (McN-A-343) and N-benzyl-3-pyrrolidyl acetate methobromide (AHR 602) on cardiac performance and noradrenaline release from terminal sympathetic fibres were measured in isolated perfused hearts of rabbits. 2 In the presence of sufficient atropine to block muscarinic receptors, high concentrations of McN-A-343 and AHR 602 caused no cardiac stimulation and there was no increase in the resting output of noradrenaline into the perfusates. 3 McN-A-343 and AHR 602 increased both the mechanical responses and the transmitter overflow evoked by electrical stimulation of the sympathetic nerves (SNS) but inhibi…

ChronotropicAtropineMalemedicine.medical_specialtyPyrrolidinesSympathetic Nervous SystemStimulationAutopharmacologyHexamethonium CompoundsPharmacologyIn Vitro TechniquesPiperazinesHexamethonium compoundchemistry.chemical_compoundNorepinephrineCocaineInternal medicineDesipramineMuscarinic acetylcholine receptorBenzyl CompoundsmedicineAnimalsPharmacologyNeuronsHeartHydrogen-Ion ConcentrationAcetylcholineElectric StimulationPerfusionQuaternary Ammonium CompoundsAtropineEndocrinologychemistryParasympathomimeticsHexamethoniumFemaleCarbamatesRabbitsDimethylphenylpiperazinium IodideAcetylcholinemedicine.drug
researchProduct

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

2019

Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver …

CyclopropanesLiver CirrhosisMaleAminoisobutyric AcidsPyrrolidinesCirrhosisSustained Virologic Responseadverse eventHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicine030212 general & internal medicinePathologie maladies infectieusesSulfonamidesmedicine.diagnostic_testLiver DiseasesPibrentasvirMicrobiologie et protistologie [entomologiephytoparasitolog.]Infectious DiseasesData Interpretation StatisticalLiver biopsyglecaprevir/pibrentasvirHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologycompensated cirrhosisMicrobiologie et protistologie [parasitologie hum. et anim.]Microbiology (medical)medicine.medical_specialtyGenotypeProlineLactams MacrocyclicHepatitis C virusAntiviral Agents03 medical and health sciencesLeucineQuinoxalinesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryGlecaprevirHepatitis C Chronicmedicine.diseaseBenzimidazolesMicrobiologie et protistologie [bacteriol.virolog.mycolog.]Transient elastographybusinesschronic kidney diseaseKidney diseaseClinical Infectious Diseases
researchProduct

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and…

2017

Background There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials led to the selection of a three-drug regimen of grazoprevir (MK-5172; an HCV NS3/4A protease inhibitor; 100 mg/day) plus ruzasvir (MK-8408; an NS5A inhibitor; 60 mg/day) plus uprifosbuvir (MK-3682; an HCV NS5B polymerase inhibitor; 450 mg/day). Part B of the studies tested this combination as a single formulation in different treatment durations in a broader population. Methods Part B of these randomised, phase 2, open-label clinical trials enrolled individuals from 15 countries who were chronically infected with H…

CyclopropanesLiver CirrhosisMalePyrrolidinesSustained Virologic ResponseGastroenterologychemistry.chemical_compound0302 clinical medicinePegylated interferonGenotype030212 general & internal medicineSulfonamideseducation.field_of_studyGastroenterologyHepatitis CMiddle Aged10219 Clinic for Gastroenterology and HepatologyGrazoprevirHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyGenotypePopulationFixed-dose combination610 Medicine & healthAntiviral AgentsHeterocyclic Compounds 4 or More RingsDrug Administration Schedule03 medical and health sciencesQuinoxalinesInternal medicineRibavirinmedicineHumans2715 GastroenterologyeducationUridinetherapyHepatologybusiness.industryRibavirinHepatitis C Chronicmedicine.diseaseAmidesThiazolesRegimenchemistryImmunology2721 HepatologyCarbamatesbusiness
researchProduct

Synthesis of 8-aminomorphans with high KOR affinity

2021

2-Azabicyclo[3.3.1]nonanes (morphans) with a (3,4-dichlorophenyl)acetyl group at 2-position and a pyrrolidino moiety at 8-position were designed as conformationally restricted analogs of piperidine-based KOR agonists. The synthesis started with 4-oxopiperidine-2-carboxylic acid comprising 13 reaction steps. At first the ketone 10 was transformed into diester 7 bearing a propionate side chain. Dieckmann condensation of diester 7 to afford bicyclic enolester 14 and subsequent Krapcho deethoxycarbonylation represent the key steps of the synthesis. The enantiomeric pyrrolidines (1S,5R,8R)-5a and (1R,5S,8S)-5a were separated by chiral HPLC. The eutomer (1S,5R,8R)-5a showed high KOR affinity (K-i…

Diastereoselective reductive aminationEnantiomeric excessStructure-affinity relationshipsPharmacologyPyrrolidinesReceptors Opioid kappaNOESY spectrumOrganic ChemistryMolecular ConformationStereoisomerismGeneral MedicineKOR agonistsEndo-configurationStructure-Activity RelationshipKOR pharmacophoreConformational restrictionChiral HPLCDihedral angleDrug DiscoveryCis/trans-configurationMorphan2-azabicyclo[3.3.1]nonaneEuropean Journal of Medicinal Chemistry
researchProduct